Arcadia Biosciences Inc (RKDA.OQ)
RKDA.OQ on NASDAQ Stock Exchange Capital Market
23.82USD
19 Apr 2018
23.82USD
19 Apr 2018
Change (% chg)
$-1.90 (-7.39%)
$-1.90 (-7.39%)
Prev Close
$25.72
$25.72
Open
$25.00
$25.00
Day's High
$25.40
$25.40
Day's Low
$23.38
$23.38
Volume
16,092
16,092
Avg. Vol
104,277
104,277
52-wk High
$66.42
$66.42
52-wk Low
$3.60
$3.60
About
Arcadia Biosciences, Inc. is an agricultural biotechnology trait company. The Company develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of developmen... (more)
No analyst recommendations are available for .
Overall
| Beta: | -- |
| Market Cap(Mil.): | $14.21 |
| Shares Outstanding(Mil.): | 42.66 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| RKDA.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 23.60 | 356.60 |
| EPS (TTM): | -0.41 | -- | -- |
| ROI: | -35.03 | 2.15 | 10.64 |
| ROE: | -78.63 | 4.15 | 13.79 |
BRIEF-Arcadia Biosciences Files Prospectus Related To Sale Of Up To 2.9 Mln Shares Of Common Stock By Selling Shareholders
* ARCADIA BIOSCIENCES FILES PROSPECTUS RELATED TO SALE OF UP TO 2.9 MILLION SHARES OF COMMON STOCK BY SELLING SHAREHOLDERS - SEC FILING Source text: (https://bit.ly/2uyTUPD) Further company coverage:
BRIEF-Arcadia Biosciences Welcomes New Chief Commercial Officer
* ARCADIA BIOSCIENCES - SARAH REITER JOINED CO'S EXECUTIVE TEAM AS CHIEF COMMERCIAL OFFICER Source text for Eikon: Further company coverage:
BRIEF-Arcadia Biosciences Announces $10 Mln Private Placement
* ARCADIA BIOSCIENCES ANNOUNCES $10 MILLION PRIVATE PLACEMENT
BRIEF-Arcadia Biosciences announces passing of board chairman George Gosbee
* Arcadia biosciences announces passing of board chairman George Gosbee Source text for Eikon: Further company coverage:
BRIEF-Arcadia Biosciences announces third-quarter financial results
* Arcadia Biosciences announces third-quarter and nine-month 2017 financial results and business highlights
Earnings vs. 
Estimates